Announcements Trials

Browse Landscape

Phase

Phase 2 1 Phase 1 1

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Breast Neoplasms 64 Neoplasms 8 Sarcoma 6 Ovarian Neoplasms 6 Squamous Cell Carcinoma of Head and Neck 5 Neoplasm Metastasis 5 Sarcoma, Ewing 4 Multiple Myeloma 4 Lymphoma, Non-Hodgkin 4 Glioma 4 Carcinoma, Non-Small-Cell Lung 4 Rhabdomyosarcoma 3 Rhabdoid Tumor 3 Prostatic Neoplasms 3 Osteosarcoma 3 Neuroblastoma 3 Melanoma 3 Medulloblastoma 3 Lymphoma 3 Liposarcoma 3 Endometrial Neoplasms 3 Colorectal Neoplasms 3 Colonic Neoplasms 3 Carcinoma, Renal Cell 3 Wilms Tumor 2 Rectal Neoplasms 2 Pancreatic Neoplasms 2 Neuroectodermal Tumors, Primitive, Peripheral 2 Lung Neoplasms 2 Kidney Neoplasms 2

Interventions

Fulvestrant 5 Letrozole 3 Capecitabine 3 ribociclib 2 exemestane 2 dalpiciclib 2 apatinib 2 Irinotecan 2 Gemcitabine 2 Anastrozole 2 tusamitamab ravtansine 1 trastuzumab deruxtecan 1 sacituzumab govitecan 1 pegfilgrastim 1 palbociclib 1 margetuximab 1 irinotecan sucrosofate 1 fluzoparib 1 abemaciclib 1 Vinorelbine 1 Trastuzumab 1 Tamoxifen 1 Paclitaxel 1 Liposomes 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

Phase 2 × Breast Cancer Metastatic × palbociclib × Clear all

NCT03322215 2024-03-08

PASIPHAE

Karolinska University Hospital

Phase 2 Terminated

Breast Cancer Metastatic

Data powered by HemOnc (CC BY 4.0) Colophon ⚡